Articles related to STATINS/CHOLESTEROL MANAGEMENT

The FDA’s Class II designation indicates that exposure or usage of ‘a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.’

“There are cholesterol quacks out there—some as smart as they are duplicitous—telling lies about cholesterol and statins, talking thousands of people into ignoring their dangerously high cholesterol.”

“Our findings highlight that daily diet matters not only for cancer risk but also for how the disease progresses once it has developed… reducing sugary drinks, targeting SORD or repurposing statins may benefit patients with colorectal cancer.” – Jihye Yun, Lead Researcher

The article presents evidence suggesting cardiovascular risk may correlate more strongly with inflammatory processes than cholesterol levels, recommending CRP monitoring alongside comprehensive biomarker assessment and lifestyle modifications targeting inflammation reduction through carbohydrate restriction.

The study identifies three scenarios where CAC testing provides limited value: “too early” (younger patients without risk factors), “too late” (elderly patients or those already on statins), and “too often” (repeated imaging after statin initiation).

While statins help lower cholesterol, they may also contribute to insulin resistance, increasing the risk of type 2 diabetes—a known risk factor for cardiovascular disease.